ClinicalTrials.gg
CompletedNCT00165841Updated May 20, 2013Results posted

Maintenance Intermittent Therapy for Symptomatic GERD Patients

A Phase 2 interventional study of Rabeprazole 20 mg in Gastroesophageal Reflux Disease, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-05-20.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.

Enrollment
13th of 39
200 · median 100
Started
2004
with 4 others
Phase 2
4 of 40
none open now
Registered
5th of 40
by date
Lead sponsor
9 of 40
Eisai Inc.

Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one is the 13th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2004, is one of 4 in phase 2, and was the 5th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →

About rabeprazole

Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing rabeprazole in Gastroesophageal Reflux as a file.
02

Study summary

The purpose of this study to determine the efficacy of 20 mg of rabeprazole given as a maintenance intermittent therapy following acute treatment for Symptomatic Gastroesophageal Reflux Disease (s-GERD).

03

Conditions studied

  • Gastroesophageal Reflux Disease

Keywords

  • non-erosive symptomatic GERD
  • GERD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female patients, 18 to 65 years of age.
  2. If female, not of by reason of surgery, radiation or menopause, or of childbearing potential, but using an approved method of since the last menstrual period, for example, intrauterine device (IUD), implant, double barrier method, or oral contraceptives for at least one cycle. Females of childbearing potential must have a negative urine pregnancy test before medication is dispensed.
  3. Patients must report a minimum three-month history of GERD symptoms. GERD symptoms are defined as heartburn with or without regurgitation or other associated GERD symptoms.
  4. Patients must have at least 4 days with heartburn per week in each of the 2 weeks prior to Screening.
  5. Patients must have no esophagitis, with no proton pump inhibitors (PPIs, prescription or OTC), H2 blockers (prescription or OTC) or prokinetics within 14 days, prior to the endoscopy.

Key Exclusion Criteria:

  1. Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric or cardiovascular system abnormalities, unless the Sponsor and Investigator agree that the nature and severity of any abnormality is unlikely to interfere with the conduct of the study, the interpretation of study results, or the health of the patient during the study.
  2. Females must not be pregnant, lactating or have a positive urine eta human chorionic gonadotropin (B-hCG) laboratory result.
  3. Patients with a history of allergy or sensitivity to proton pump inhibitors or to their inactive ingredients.
  4. Patients with known gastric ulcer, duodenal ulcer, infectious or inflammatory conditions of the small or large intestine, malabsorption syndromes, obstruction, a history of gastrointestinal , or prior gastric or intestinal surgery (including vagotomy).
  5. Patients who have a history of Barrett's esophagus, esophageal stricture, or pyloric stenosis.
  6. Patients with a history of endoscopically-proven esophagitis any time in the past.
  7. Patients who have taken proton pump inhibitors (PPIs, prescription or OTC), H2 blockers (prescription or OTC) or prokinetics within 14 days, prior to Screening endoscopy, or any of these medications within 7 days prior to the single-blind placebo run-in period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
200 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Rabeprazole 20 mg

  • Experimental
    Rabeprazole 20 mg

    Drug: Rabeprazole 20 mg

Interventions

  • rabeprazole sodium tablet 20 mg once daily

    Also known as: rabeprazole

06

What researchers measure

Primary outcomes

  1. The Percentage of Heartburn-free Days (24-hour Periods) During the 6-month Maintenance Treatment Phase (ITT Population).

    The percentage of heartburn-free days during the 6-month Maintenance Treatment Phase in patients treated with rabeprazole 20 mg compared to patients who received placebo in the ITT Population. Heartburn-free day was defined as no heartburn in both the daytime and nighttime period on a given day. Note a total 388 subjects were enrolled at the beginning of Acute Phase and 200 subjects were enrolled into the double-blind 6-month maintenance treatment phase.

    Time frame: 6 months double-blind maintenance phase

Secondary outcomes

  1. The Percent of Heartburn-free Daytime Period During the 6-month Maintenance Treatment Phase

    The percentage of heartburn-free daytime period is presented cumulatively including all data collected during the 6-month Maintenance Phase

    Time frame: 6-month maintenance phase

  2. The Percent of Heartburn-free Nighttime Period During the 6-month Maintenance Treatment Phase

    The percentage of heartburn-free nighttime period is presented cumulatively including all data collected during the 6-month

    Time frame: 6-month maintenance phase

07

Results

Posted Dec 3, 2009

Participant flow

This study was recruited at 47 centers in the US during the period of 7-Oct-2004 and 12-Dec-2005.

Participant flow — Overall Study
MilestoneRabeprazole 20 mgPlacebo
Started10397
Completed7335
Not completed3062
Withdrew: Adverse event23
Withdrew: Lack of efficacy633
Withdrew: Lost to follow-up44
Withdrew: Withdrawal by subject78
Withdrew: Physician decision10
Withdrew: Protocol violation68
Withdrew: Other35
Withdrew: Medication noncompliance11

Outcome measures

PrimaryThe Percentage of Heartburn-free Days (24-hour Periods) During the 6-month Maintenance Treatment Phase (ITT Population).

The percentage of heartburn-free days during the 6-month Maintenance Treatment Phase in patients treated with rabeprazole 20 mg compared to patients who received placebo in the ITT Population. Heartburn-free day was defined as no heartburn in both the daytime and nighttime period on a given day. Note a total 388 subjects were enrolled at the beginning of Acute Phase and 200 subjects were enrolled into the double-blind 6-month maintenance treatment phase.

Time frame:
6 months double-blind maintenance phase
Reported as:
Mean · Percentage of Days
The Percentage of Heartburn-free Days (24-hour Periods) During the 6-month Maintenance Treatment Phase (ITT Population).
Percentage of DaysRabeprazole 20 mgPlacebo
The Percentage of Heartburn-free Days (24-hour Periods) During the 6-month Maintenance Treatment Phase (ITT Population).82.58 ± 14.3962.17 ± 29.93
Statistical analysis
  • Rabeprazole 20 mg vs Placebo · t-test, 2 sided · p = <0.0001 (p-value was adjusted for multiple comparisons.)The primary analysis was on the ITT population using all observed data collected from Day 1 of the maintenance phase until the endpoint.
SecondaryThe Percent of Heartburn-free Daytime Period During the 6-month Maintenance Treatment Phase

The percentage of heartburn-free daytime period is presented cumulatively including all data collected during the 6-month Maintenance Phase

Time frame:
6-month maintenance phase
Reported as:
Mean · %

Results for this outcome have not been posted.

SecondaryThe Percent of Heartburn-free Nighttime Period During the 6-month Maintenance Treatment Phase

The percentage of heartburn-free nighttime period is presented cumulatively including all data collected during the 6-month

Time frame:
6-month maintenance phase
Reported as:
Mean · %

Results for this outcome have not been posted.

Adverse events

Collected over 6 month maintenance phase. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rabeprazole 20 mg———
Placebo———
Most frequent serious events
Most frequent serious events
EventRabeprazole 20 mgPlacebo
Gallstone pancreatitisGastrointestinal disorders0/1031/97
PneumoniaInfections and infestations0/1031/97
Chest painGeneral disorders1/1030/97
Schizoaffective disorder/depressionNervous system disorders1/1030/97
Most frequent other events
Most frequent other events
EventRabeprazole 20 mgPlacebo
DiarrheaGastrointestinal disorders7/1031/97
Esophageal erosionGastrointestinal disorders2/1036/97
Hiatus herniaGastrointestinal disorders6/1034/97
EsophagitisGastrointestinal disorders4/1035/97
NauseaGastrointestinal disorders5/1033/97
HeadacheNervous system disorders5/1033/97
CoughRespiratory, thoracic and mediastinal disorders5/1032/97
Erosive gastritisGastrointestinal disorders2/1034/97
Viral gastroenteritisInfections and infestations0/1034/97
SinusitisInfections and infestations2/1034/97

Baseline characteristics

Age Continuous
Age Continuous(years)Rabeprazole 20 mgPlaceboTotal
Mean46.0 ± 11.6746.6 ± 11.6946.3 ± 11.66
Sex: Female, Male
Sex: Female, Male(Participants)Rabeprazole 20 mgPlaceboTotal
Female6459123
Male323264
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rabeprazole 20 mgPlaceboTotal
American Indian or Alaska Native011
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American91019
White7464138
More than one race000
Unknown or Not Reported121628
08

Study locations

1 site
  • Quality Care Medical Center Inc.
    Vista, California 92085, United States
09

References and documents

Publications

  • Fass R, Delemos B, Nazareno L, Kao R, Xiang J, Lu Y. Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study. Aliment Pharmacol Ther. 2010 May;31(9):950-60. doi: 10.1111/j.1365-2036.2010.04254.x. Epub 2010 Feb 2. PubMed 20132154 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Dec 2005 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 14, 2005
Start
Oct 2004
Primary completionActual
Dec 2005
CompletionActual
Jun 2008
Results first posted
Dec 3, 2009
Last update
May 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00165841
Lead sponsor
Eisai Inc.
First posted
Sep 14, 2005
Start date
Oct 2004
Primary completion
Dec 2005
Completion
Jun 2008
Results posted
Dec 3, 2009
Last update
May 20, 2013

Study contacts

Yufang Lu
study director · Eisai Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion